Transactions
2
Insider / Vaxcyte, Inc.
Jodar Luis
Chief Medical Officer at Vaxcyte, Inc.
- Company
- Vaxcyte, Inc.
- Ticker
- PCVX
- First filing on record
- September 9, 2026
- Latest trade on record
- September 4, 2026
- SEC filings
- EDGAR ↗
Jodar Luis, Chief Medical Officer at Vaxcyte, Inc., has disclosed 2 transactions in PCVX since September 9, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed September 9, 2026, 5 days after the trade; 2 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
0
Avg. disclosure lag
5.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Jodar Luis reported 2 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 140,886 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| PCVX | Other A | September 4, 2026 | September 9, 2026 | 5d | 88,254 | — | — | latederivative | Form 4 ↗ | |
| PCVX | Other A | September 4, 2026 | September 9, 2026 | 5d | 52,632 | — | — | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| September 9, 2026 | Form 4 | 0002151661-26-000004 | 2 | published | EDGAR ↗ |
Other insiders at Vaxcyte, Inc.
- Wassil Jim CHIEF OPERATING OFFICER 41 rows
- PICKERING GRANT CHIEF EXECUTIVE OFFICER 32 rows
- Cowan Elvia SVP, Finance & CAO 24 rows
- GUGGENHIME ANDREW PRESIDENT AND CFO 21 rows
- Dhaliwal Harpreet S. Chief Technical Ops Officer 12 rows
- Gilbert Halley E Director 7 rows
- BRANDICOURT OLIVIER Director 6 rows
- Drapeau Anne S Director 2 rows
- Furey John Director 2 rows
- Lee Jacks Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: Vaxcyte, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 2 | September 9, 2026 | September 9, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.